- Home
- TWIN vs SKYE Comparison
TWIN vs SKYE Comparison
Compare TWIN & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWIN
- SKYE
- Stock Information
- Founded
- TWIN 1918
- SKYE 2012
- Country
- TWIN United States
- SKYE United States
- Employees
- TWIN N/A
- SKYE N/A
- Industry
- TWIN Industrial Machinery/Components
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- TWIN Industrials
- SKYE Health Care
- Exchange
- TWIN Nasdaq
- SKYE Nasdaq
- Market Cap
- TWIN 152.3M
- SKYE 94.0M
- IPO Year
- TWIN N/A
- SKYE N/A
- Fundamental
- Price
- TWIN $11.08
- SKYE $2.73
- Analyst Decision
- TWIN
- SKYE Buy
- Analyst Count
- TWIN 0
- SKYE 6
- Target Price
- TWIN N/A
- SKYE $18.67
- AVG Volume (30 Days)
- TWIN 25.7K
- SKYE 167.7K
- Earning Date
- TWIN 02-05-2025
- SKYE 02-09-2025
- Dividend Yield
- TWIN 1.47%
- SKYE N/A
- EPS Growth
- TWIN N/A
- SKYE N/A
- EPS
- TWIN 0.68
- SKYE N/A
- Revenue
- TWIN $304,470,000.00
- SKYE N/A
- Revenue This Year
- TWIN N/A
- SKYE N/A
- Revenue Next Year
- TWIN N/A
- SKYE N/A
- P/E Ratio
- TWIN $16.24
- SKYE N/A
- Revenue Growth
- TWIN 6.98
- SKYE N/A
- 52 Week Low
- TWIN $10.22
- SKYE $2.25
- 52 Week High
- TWIN $18.00
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- TWIN 42.13
- SKYE 37.40
- Support Level
- TWIN $10.22
- SKYE $2.31
- Resistance Level
- TWIN $11.86
- SKYE $3.04
- Average True Range (ATR)
- TWIN 0.49
- SKYE 0.30
- MACD
- TWIN -0.06
- SKYE 0.07
- Stochastic Oscillator
- TWIN 46.49
- SKYE 44.68
About TWIN Twin Disc Incorporated
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.